News: Novartis

06.09.2010 | Medical News Today: Seasonal Influenza Vaccine Distribution Still Below Levels Needed To Meet Guidelines, Despite Growth Worldwide

A new IFPMA study(1), announced at the "Options for the Control of Influenza VII" conference in Hong Kong, shows that global vaccine coverage remains uneven and low overall, despite total distribution of seasonal influenza vaccines nearly doubling over the last six years. The (…)

[Read article]

[Source: Medical News Today]

03.09.2010 | Marketwire: Bausch + Lomb to Acquire Miochol-E

Highlighted Links Bausch + Lomb ROCHESTER, NY-(Marketwire - September 3, 2010) - Bausch + Lomb, the global eye health company, has announced that it has concluded its acquisition of a portion of the assets and intellectual property for Miochol-E from Affiliates of Novartis AG. (…)

[Read article]

[Source: Marketwire]

03.09.2010 | Medical News Today: New Antimalarial Compound Shows Promise For Drug Resistant Malaria

Scientists are developing a new antimalarial drug with a novel mechanism of action which shows promise for clearing a Plasmodium (malaria parasite) infection after a single dose, according to an article published in the journal Science. Scientists say the antimalarial (…)

[Read article]

[Source: Medical News Today]

03.09.2010 | Business Wire: Research and Markets: Thailand Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/60383e/thailand_pharmaceu) has announced the addition of the "Thailand Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Thailand Pharmaceuticals and Healthcare (…)

[Read article]

[Source: Business Wire]

03.09.2010 | BioSpace: Bausch & Lomb (BOL) to Acquire Miochol(R)-E

ROCHESTER, NY-(Marketwire - September 03, 2010) - Highlighted Links Bausch + Lomb Bausch + Lomb, the global eye health company, has announced that it has concluded its acquisition of a portion of the assets and intellectual property for Miochol-E from Affiliates of Novartis (…)

[Read article]

[Source: BioSpace]

02.09.2010 | ScienceDaily: New Type of Anti-Malarial Compound Discovered

ScienceDaily (Sep. 2, 2010) An international team led by scientists from The Scripps Research Institute, the Swiss Tropical Institute, the Genomics Institute of the Novartis Research Foundation and the Novartis Institute for Tropical Diseases has discovered a promising new drug (…)

[Read article]

[Source: ScienceDaily]

02.09.2010 | ScienceDaily: Molecules Involved in 'Touch' Identified: Could Lead to New Treatments for Pain, Deafness and Cardiac Function

ScienceDaily (Sep. 2, 2010) Scripps Research Institute scientists have identified two proteins with potential to be important targets for research into a wide range of health problems, including pain, deafness, and cardiac and kidney dysfunction. See Also: Health & Medicine (…)

[Read article]

[Source: ScienceDaily]

02.09.2010 | Medical News Today: Novartis Drug Tasigna Approved In Switzerland After Fast-track Review For Treatment Of Patients With Newly Diagnosed Ph+ CML

The Swiss health authority Swissmedic has granted approval for Tasigna (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new (…)

[Read article]

[Source: Medical News Today]

02.09.2010 | Business Wire: Research and Markets: Trends in Generics Industry Ownership: Evaluating Changing Industry Paradigms and Emerging Players | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/886118/trends_in_generics) has announced the addition of the "Trends in Generics Industry Ownership: Evaluating Changing Industry Paradigms and Emerging Players" report to their offering. (…)

[Read article]

[Source: Business Wire]

02.09.2010 | Business Wire: Research and Markets: Examine Norway's Pharmaceutical Market with This Essential Analysis to 2014 As the Market Generated Total Revenues of $2,011.5 Million In 2009 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ebf598/norway_pharmaceuti) has announced the addition of the "Norway Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)

[Read article]

[Source: Business Wire]

01.09.2010 | Business Wire: Research and Markets: Argentina Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2745c9/argentina_pharmace) has announced the addition of the "Argentina Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Argentina Pharmaceuticals and Healthcare (…)

[Read article]

[Source: Business Wire]

31.08.2010 | Medical News Today: Also In Global Health News: GM Mosquitoes; Iodine Deficiency In Nepal; South African Health Workers Strike; Novartis To Build Vaccine Plant In Brazil;

Malaysia Considers GM Mosquito Release To Control Dengue Fever Malaysia is still "considering releasing" up to 3,000 mosquitoes that are genetically modified to "combat dengue fever, in a landmark field trial that has come in for criticism from environmentalists," Agence (…)

[Read article]

[Source: Medical News Today]

31.08.2010 | Business Wire: Research and Markets: Philippines Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/66a1b1/philippines_pharma) has announced the addition of the "Philippines Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Philippines Pharmaceuticals and (…)

[Read article]

[Source: Business Wire]

31.08.2010 | Business Wire: Research and Markets: Australia Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c31cef/australia_pharmace) has announced the addition of the "Australia Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Australia Pharmaceuticals and Healthcare (…)

[Read article]

[Source: Business Wire]

31.08.2010 | Business Wire: Research and Markets: Nigeria Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/23871e/nigeria_pharmaceut) has announced the addition of the "Nigeria Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Nigeria Pharmaceuticals and Healthcare Report (…)

[Read article]

[Source: Business Wire]

31.08.2010 | BioSpace: BioCision, LLC Signs Agreement with SERVA Electrophoresis GmbH for Distribution of CoolTech Products in Europe

MILL VALLEY, Calif. - March 26, 2010 - BioCision LLC today announced that it has signed a European distribution agreement with SERVA Electrophoresis, a global supplier of reagents for scientific research. SERVA Electrophoresis will sell BioCision s entire portfolio of (…)

[Read article]

[Source: BioSpace]

31.08.2010 | BioSpace: BioCision, LLC Lands New Distribution Partner with Biophoretics Deal

MILL VALLEY, Calif. February 11, 2010 - BioCision LLC, the CoolRack ¢ company, announced today that it has entered into a distribution agreement with Biophoretics, a developer and distributor of advanced tools for scientific research. Biophoretics will sell BioCision s entire (…)

[Read article]

[Source: BioSpace]

31.08.2010 | BioSpace: BioCision, LLC Signs Distribution Deal with Capital Biosciences, Inc.

MILL VALLEY, Calif. - BioCision LLC, the CoolRack ¢ company, announced today that is has reached an agreement with Capital Biosciences Inc. for the distribution of BioCision's products, which standardize the handling and processing of temperature-sensitive samples. œCapital (…)

[Read article]

[Source: BioSpace]

31.08.2010 | Bionity.com: Novartis drug Tasigna approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML

31.08.2010 - Swissmedic has granted approval for Tasigna (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option (…)

[Read article]

[Source: Bionity.com]

31.08.2010 | Bionity.com: Novartis receives FDA approval of Tekamlo

31.08.2010 - The US Food and Drug Administration (FDA) approved Tekamlo (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna (aliskiren) with the widely used calcium channel (…)

[Read article]

[Source: Bionity.com]

30.08.2010 | Marketwire: King Pharmaceuticals Appoints Jeffrey Bailey Chief Commercial Officer

BRISTOL, TN-(Marketwire - August 30, 2010) - King Pharmaceuticals, Inc. (NYSE: KG) announced today the appointment of Jeffrey A. Bailey to the position of Chief Commercial Officer. Mr. Bailey will be responsible for the Company's commercial activities in the branded (…)

[Read article]

[Source: Marketwire]

30.08.2010 | Medical News Today: At NACDS Pharmacy & Technology Conference, Cardinal Health Helps Retail Pharmacies Fight Prescription Drug Abuse

At the NACDS Pharmacy & Technology Conference, taking place August 28-31 in San Diego, Calif., Cardinal Health will encourage attendees to learn more about how they can get involved in the fight against prescription drug abuse. Today, prescription medication abuse is a (…)

[Read article]

[Source: Medical News Today]

30.08.2010 | Business Wire: Research and Markets: This Essential Analysis Examines the Historical and Forecast Performance for Eli Lilly In the Prescription Pharma Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/37adf0/eli_lilly_co_p) has announced the addition of the "Eli Lilly & Co.: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: This Report Highlights Sweden's Pharmaceutical Sector in Terms of Market Share, Key Trends, Market Players and Competitive Scenario in the Market | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/b87073/sweden_pharmaceuti) has announced the addition of the "Sweden Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: This Analysis Examines the Historical and Forecast Performance for Novartis in the Prescription Pharma Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/a9fe9d/novartis_ag_pharm) has announced the addition of the "Novartis AG: PharmaVitae Profile" company profile to their offering. This analysis examines the historical and forecast (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Maven Semantic: Database of Dermatology Research | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Dermatology research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: This Analysis Examines the Historical and Forecast Performance for Johnson & Johnson in the Ethical Pharmaceutical Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/aabcf1/johnson_johnson) has announced the addition of the "Johnson & Johnson: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]

30.08.2010 | BioSpace: BioCision, LLC and Biohit Partner to Co-Promote Complementary Products

MILL VALLEY, Calif., March 31 /PRNewswire/ - BioCision LLC today announced that it has agreed to a co-promotion program with Biohit Inc. (www.us.biohit.com). Biohit's ErgoTube microcentrifuge tubes will now be branded and sold by both Biohit Inc. and BioCision. In addition, (…)

[Read article]

[Source: BioSpace]

30.08.2010 | BioSpace: Portola Pharmaceuticals, Inc. Announces That Phase 2 INNOVATE-PCI Trial With Elinogrel Achieved Objectives; Novartis AG to Start Final-Stage Test of Blood Thinner

STOCKHOLM, SWEDEN-(Marketwire - August 30, 2010) - Portola Pharmaceuticals, Inc. today announced results from the Phase 2 INNOVATE-PCI study of its investigational antiplatelet drug, elinogrel, the only competitive, reversible direct-acting P2Y12 ADP receptor antagonist. (…)

[Read article]

[Source: BioSpace]

30.08.2010 | Bionity.com: Novartis completes 77% majority ownership of Alcon adding new growth platform in eye care to its leading healthcare portfolio

30.08.2010 - Novartis announced that it has completed its purchase of Alcon stock from Nestl resulting in 77% ownership of Alcon. This has been achieved by completing the acquisition of the remaining 52% of Alcon shares owned by Nestl for a total of USD 28.3 billion. Alcon (…)

[Read article]

[Source: Bionity.com]

29.08.2010 | Marketwire: Portola Pharmaceuticals Announces Presentation of New Pharmacodynamic Data From Phase 2 Trial of Investigational Factor Xa Inhibitor, Betrixaban

STOCKHOLM, SWEDEN-(Marketwire - August 29, 2010) - Portola Pharmaceuticals, Inc. today announced additional pharmacodynamic data from a pre-specified analysis of EXPLORE-Xa, a Phase 2 dose-finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. During (…)

[Read article]

[Source: Marketwire]

28.08.2010 | Medical News Today: Hypertension Drug Tekamlo (Aliskiren And Amlodipine) Approved By FDA

Novartis' single pill combination of aliskiren and amlopidine - Tekamlo - has been approved by the Food and Drug Administration (FDA) for the treatment of hypertension. Data revealed that Tekamlo significantly reduced blood pressure compared to amlodipine or aliskiren (…)

[Read article]

[Source: Medical News Today]

27.08.2010 | Marketwire: Novartis receives FDA approval of TekamloTM, a single-pill combination of aliskiren and amlodipine to treat high blood pressure

EAST HANOVER, NJ-(Marketwire - August 27, 2010) - Tekamlo combines in a single-pill the only approved direct renin inhibitor, Tekturna, with the widely prescribed calcium channel blocker, amlodipine Data showed Tekamlo significantly reduced blood pressure compared to (…)

[Read article]

[Source: Marketwire]

27.08.2010 | Business Wire: Research and Markets: Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/db0b08/type_2_diabetes) has announced the addition of GlobalData 's new report "Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017" to their offering. Type 2 Diabetes - (…)

[Read article]

[Source: Business Wire]

12.08.2010 | NCBI PubMed: Low powder mass filling of dry powder inhalation formulations.

Context: The successful accurate dosing and filling of powders at fill masses of

[Read article]

[Source: NCBI PubMed]

25.08.2010 | NCBI PubMed: Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study.

OBJECTIVE.: To evaluate changes in vascular and musculoskeletal involvement in subjects in the Scleroderma Lung Study (SLS), a multicenter, double-blind, randomized, controlled trial comparing placebo treatment to oral cyclophosphamide for 1 year in systemic sclerosis (SSc) (…)

[Read article]

[Source: NCBI PubMed]

25.08.2010 | NCBI PubMed: Structural Evidence of Glycoprotein Assembly in Cellular Membrane Compartments Prior to Alphavirus Budding.

Membrane glycoproteins of alphavirus play a critical role in the assembly and budding of progeny virions. However, knowledge regarding transport of viral glycoproteins to the plasma membrane is obscure. In this study, we investigate the role of cytopathic vacuole type II (…)

[Read article]

[Source: NCBI PubMed]

26.08.2010 | ScienceDaily: Scientists Unveil Structure of Adenovirus, the Largest High-Resolution Complex Ever Found

ScienceDaily (Aug. 26, 2010) After more than a decade of research, Scripps Research Institute scientists have pieced together the structure of a human adenovirus - the largest complex ever determined at atomic resolution. The new findings about the virus, which causes (…)

[Read article]

[Source: ScienceDaily]

26.08.2010 | Medical News Today: Keystone Symposia To Hold Conference In Seattle On Immunological Mechanisms Of Vaccination

Keystone Symposia on Molecular and Cellular Biology will convene its conference on "Immunological Mechanisms of Vaccination" in Seattle, Washington from October 27 to November 1, 2010 at Sheraton Seattle Hotel. This is the first conference of Keystone Symposia's 40th meeting (…)

[Read article]

[Source: Medical News Today]

26.08.2010 | Business Wire: Research and Markets: This Essential World Pharmaceutical Market Analysis Digest Guide with Forecasts Predicts the Market Will Stabilize the Years Up To 2014 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e03d6e/world_pharmaceutic) has announced the addition of the "World Pharmaceutical Market Analysis - A Digest Guide, 2010-2014" report to their offering. World Pharmaceutical Market (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Research and Markets: Fixed Dose Combination Products - Identify the Proven Strategies for Developing & Commercializing FDC Products | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/614240/fixed_dose_combina) has announced the addition of the "Fixed Dose Combination Products" report to their offering. Fixed dose combination (FDC) products are becoming increasingly (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Maven Semantic: Genetically Modified Organisms (GMO) Database | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Genetically Modified Organisms research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not (…)

[Read article]

[Source: Business Wire]